IgA nephropathy associated with Crohn's disease

doi:10.5662/wjm.v13.i3.67

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 3

This Article

Academic Content and Language Evaluation of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3747)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-1) series.

Item

Count

PDF

WORD

HTML

1984

Figures (1-2)

209

Tables (1-1)

137

Sum=2442

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

128

Download

383

Sum=511

Publishing Process of This Article

Item

Count

Browse

175

Download

480

Sum=655

Jun 20, 2023 (publication date) through May 18, 2024

Times Cited of This Article

Times Cited (1)

Journal Information of This Article

Publication Name

World Journal of Methodology

ISSN

2222-0682

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Methodol. Jun 20, 2023; 13(3): 67-78
Published online Jun 20, 2023. doi: 10.5662/wjm.v13.i3.67

Table 1 Reported cases of Crohn's disease with IgA nephropathy

Age (yr)	Sex	Clinical course	CD disease type	IgAN MEST-C grade	CD treatment	IgAN treatment	CD and IgAN worsened simultaneously
20	Female	CD(y)→IgAN(y)	Ileocolitis	NR	SASP	nothing	+
25	Male	CD(4y)→IgAN(12y)	Ileocolitis	NR	ED only	NR	+
18	Male	IgAN(NR)→CD(2y)	colitis	NR	5-ASA	ACE-I	NR
24	Male	CD(NR)→IgAN(3y)	NR	NR	5-ASA	NR	-
38	Male	CD(NR)→IgAN(6y)	NR	NR	PSL+5-ASA →IFX	ACE-I	+
40	Female	CD(NR)→IgAN(5y)	colitis	NR	5-ASA	ARB	+
38	Male	CD(NR)→IgAN(16y)	Ileocolitis	NR	5-ASA	NR	NR
40	Male	CD(NR)→IgAN(12y)	NR	NR	PSL+5-ASA	PSL	+
34	Female	IgAN(4y)→CD(5y)	Ileocolitis	NR	ED only	PSL	+
25	Male	CD(25y)→IgAN(33y)	NR	M1E1S1T1C1	ADA	MPT→PSL, ACE-I	-
24	Male	CD(22y)→IgAN(24y)	Ileitis	M1E0S1T1C2	IFX →UST	MPT→PSL	-
10	Male	CD(1y)→IgAN(7y)	colitis	M1E0S0T0C0	IFX	IFX→ADA, PSL	+
40	Male	CD(NR)→IgAN(39y)	NR	M1E0S1T0C1	AZA	PSL	-
31	Male	CD(16)→IgAN(18y)	Ileocolitis	M1E0S1T1C0	PSL+5-ASA	PSL	+
46	Male	IgAN(17y)→CD(40y)→IgAN(46y)	NR	M1E0S0T0C1	5-ASA, AZA, IFX	PSL	+
15	Female	CD(16)→IgAN(18y)	NR	NR	5-ASA, PSL	IFX	+
13	Male	IgAN(10y)→CD(13y)	NR	M1E0S0T0C1	PSL, SASP	PSL, CPA, ACE-I	+
9	Male	CD(9)→IgAN(11y)	Ileitis	M1E0S0T1C0	ADA	ADA →AZA; MPT, PSL, ACE-I	-
39	Female	CD(32)→IgAN(39y)	NR	M1E0S1T0C0	ADA, AZA	ARB, ADA→IFX	+
27	Male	IgAN(22y)→CD(27y)	NR	M1E0S1T2C1	5-ASA, IFX	MPT, MMF, CsA	+
18	Male	CD(9)→IgAN(11y)	NR	M1E1S1T1C2	5-ASA	PSL, CPA	+
22	Male	IgAN(8y)→CD(22y)	NR	M1E1S1T1C0	SASP, AZA	PSL, 5-ASA	+
36	Male	CD(30)→IgAN(36y)	NR	M1E0S0T2C0	5-ASA, AZA	ACE-I	-
29	Male	IgAN(24y)→CD(29y)	colitis	NR	PSL	non	+
10	Male	CD(30)→IgAN(36y)	Ileocolitis	M1E0S0T0C0	ADA, AZA, budesonide	PSL	+

CD: Crohn's disease; IgAN: IgA nephropathy; ED: Elemental diet; PSL: Prednisolone; MPT: Methylprednisolone pulse therapy; SASP: Salazosulfapyridine; 5-ASA: 5-aminosalicylic acid; CPA: Cycrophosphamid; AZA: Azathioprine; IFX: Infliximab; ADA: Adalimumab; UST: Usutekinumab; CsA: Cyclosporin; MMF: Mycophenolate mofetil; ACE-I: Angiotensin converting enzyme inhibitor; ARB: Angiotensin receptor blocker; NR: Not reported.

Citation: Tamura H. IgA nephropathy associated with Crohn's disease. World J Methodol 2023; 13(3): 67-78
URL: https://www.wjgnet.com/2222-0682/full/v13/i3/67.htm
DOI: https://dx.doi.org/10.5662/wjm.v13.i3.67